MONARCH 2: overall survival of Abemaciclib plus Fulvestrant in patients with HR+, HER2- advanced breast cancer
Abemaciclib ( Verzenios ) is an oral, selective cyclin-dependent kinase 4 & 6 inhibitor, approved for hormone receptor-positive ( HR+ ), human epidermal growth factor receptor 2-negative ( HER2- ) advanced breast cancer ( ABC ) as monotherapy for endocrine refractory disease and with endocrine therapy for initial treatment and after progression on endocrine therapy.
In the MONARCH 2 trial, Abemaciclib + Fulvestrant significantly improved progression-free survival ( PFS ) compared to placebo + Fulvestrant ( median: 16.4 m vs 9.3 m; hazard ratio, HR: 0.553 ) with a generally tolerable safety profile.
Researchers have reported the overall survival ( OS ) results of the prespecified interim.
MONARCH 2 was a global, randomized, double-blind phase 3 trial of Abemaciclib + Fulvestrant or Placebo + Fulvestrant in pre- or perimenopausal ( with ovarian suppression ) and postmenopausal women with advanced endocrine therapy resistant HR+, HER2- advanced breast cancer.
669 patients were randomized 2:1, stratified based on site of metastasis ( visceral, bone-only, or other ) and resistance to prior endocrine therapy ( primary vs secondary ).
Abemaciclib or Placebo 150 mg was dosed Q12H, and Fulvestrant 500 mg was administered per label.
The primary objective was investigator-assessed progression-free survival. Overall survival ( OS ) was a gated secondary endpoint.
The boundary p-value for the interim analysis was 0.0208.
At the prespecified interim analysis, 338 deaths ( 77% of the planned 441 events ) were observed in the ITT population with a median overall survival of 46.7 months for Abemaciclib + Fulvestrant and 37.3 months for Placebo + Fulvestrant ( HR: 0.757; 95% CI: 0.606, 0.945; P = 0.0137 ).
These results met the predefined boundary for significance and are thus definitive.
Overall survival benefit was consistent in all stratification factors; among stratification factors, more pronounced effects were observed in subgroups of visceral disease ( HR: 0.675 ) and primary resistance to prior endocrine therapy ( HR: 0.686 ).
PFS2 ( HR: 0.675; 95% CI: 0.558, 0.816 ) and time to chemotherapy ( HR: 0.622; 95% CI: 0.499, 0.775 ) were also significantly improved.
Safety data were consistent with known Abemaciclib safety profile.
In conclusion, treatment with Abemaciclib plus Fulvestrant has provided a statistically significant and clinically meaningful median overall survival benefit of 9.4 months to pre- or perimenopausal and postmenopausal patients with HR+, HER2- advanced breast cancer who progressed on endocrine therapy with no new safety signals observed. ( Xagena )
Source: ESMO ( European Society of Medical Oncology ) Meeting, 2019
FDA has approved Ayvakit, the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Ayvakit ( Avapritinib ) for the treatment of adults...
Acid reflux drugs that are sometimes recommended to ease stomach problems during cancer treatment may have an unintended side effect:...
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Dapagliflozin has reduced the incidence of heart failure worsening or cardiovascular death in a sub-analysis from landmark phase III DAPA-HF trial
New data from a sub-analysis of the landmark phase III DAPA-HF ( Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure...
Renal and cardiovascular effects of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease
Chronic kidney disease ( CKD ) risk is elevated in patients with type 2 diabetes mellitus ( T2DM ). Disease...
FDA has approved Qinlock, first drug for fourth-line treatment of advanced gastrointestinal stromal tumors
The FDA ( U.S. Food and Drug Administration ) has approved Qinlock ( Ripretinib ) tablets as the first new...
Tabrecta for the treatment of adult patients with MET-positive non-small cell lung cancer: FDA approved
The FDA ( U.S. Food and Drug Administration ) has approved Tabrecta ( Capmatinib ) for the treatment of adult...
SGLT2 inhibitors, compared with DPP-4 inhibitors, associated with reduced risk of serious renal events
The objective of a cohort study was to assess the association between use of sodium-glucose co-transporter 2 ( SGLT2 )...
Primary analysis of CITYSCAPE study of the anti-TIGIT antibody Tiragolumab plus Atezolizumab versus Atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC
The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...
MONARCH 2: subgroup analysis of patients receiving Abemaciclib + Fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer
In MONARCH 2 ( M2 ), Abemaciclib ( Verzenios ), an oral selective cyclin dependent kinase 4 & 6 inhibitor,...